Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial

Research output: Contribution to journalJournal articlepeer-review

  1. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes

    Research output: Contribution to journalJournal articlepeer-review

  2. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

    Research output: Contribution to journalComment/debatepeer-review

  3. The circadian rhythm of calcium and bone homeostasis in Maasai

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Schizophrenia is associated with a lowered bone mineral density. The antidiabetic and body weight lowering glucagon-like peptide-1 receptor agonist liraglutide has shown to mitigate overweight and impaired glucose tolerance associated with olanzapine and clozapine. As liraglutide has been proposed to affect bone metabolism, we evaluated the effect of liraglutide on bone turnover markers (BTM) in patients with prediabetes and schizophrenia treated with olanzapine or clozapine. Patients diagnosed with a schizophrenia spectrum disorder treated with the antipsychotic compounds clozapine and/or olanzapine, having prediabetes and a BMI above 27 kg/m2 were randomized to 16 weeks of treatment with liraglutide or placebo. Fasting state serum sampled in the morning from patients (n=78) were analysed for the BTM collagen type 1 C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP). After 16 weeks of treatment, no significant changes of neither P1NP nor CTX were observed when comparing liraglutide to placebo. No association between changes of bone turnover markers and change of body weight were found in the group treated with liraglutide. In conclusion, no treatment effect on CTX nor P1NP was observed, and thus, this study does not raise any concerns in patients with schizophrenia and prediabetes treated with liraglutide regarding bone-related adverse effects.

Original languageEnglish
Article number113670
JournalPsychiatry Research
Publication statusPublished - Feb 2021

    Research areas

  • Antipsychotics, Bone metabolism, Collagen type 1 C-telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP)

ID: 61676087